To provide a set of biomarkers for nerve cognitive disorders characterized by tau toxicity, especially, Alzheimer disease.SOLUTION: The present invention relates to a panel of biomarkers which contain protein phosphatase 1 regulatory sub-unit 14A and/or 2',3'-annular nucleotide 3'- phosphodiesterase and/or phosphorized tau or a fragment thereof, and a method for using the same for diagnosing, stage-classifying, treating and evaluating response of medical treatment of nerve cognitive disorders characterized by tau toxicity, especially, Alzheimer disease. The present invention describes the biomarkers disclosed in the present description are elevated in a brain of a subject at a progressed stage of the nerve cognitive disorder (break stage V/VI) and/or adjusted in CSF of an AD subject compared with a cognitively affected non-AD control; and/or adjusted responding to two kinds of casein kinase 1 delta inhibitor.SELECTED DRAWING: None
BIOMOLECULE RELATING TO ALZHEIMER DISEASE